Mebeverine is a drug whose major therapeutic role is in the treatment of irritable bowel syndrome (IBS) and the associated abdominal cramping. It works by relaxing the muscles in and around the gut. It is a musculotropic antispasmodic drug without anticholinergic side-effects. The drug is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and is marketed as Colofac, Duspatal, Colotal, Colospa, Mebeverine(e-i-a), Rudakol, Boots IBS relieve, Fomac, Mebecon and Duspatalin by Abbott Laboratories.
Irritable bowel syndrome associated with organic lesions of the gastrointestinal tract such as; diverticulosis and diverticulitis, regional enteritis, disease of the gall bladder and gall ducts, gastric and duodenal ulcers, dysentery, and aspecific or specific inflammation of the digestive tract.
Mebeverine should be taken 20 minutes before meals.
Mode of action
Mebeverine is an antimuscarinic. It belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. This relieves painful muscle spasms of the gut, without affecting its normal motility. Mebeverine is used to relieve symptoms of irritable bowel syndrome and related intestinal disorders that are the result of spasms in the intestinal muscles. These include colicky abdominal pain and cramps, diarrhoea alternating with constipation and flatulence (wind).
Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, it has dual mode of action which normalizes the small bowel motility.
^in 't Veld BA, van Puyenbroek E, Stricker BH. (1997). Hypersensitivity reactions to use of mebeverine. pp. 1392–5. Ned Tijdschr Geneeskd. 1997 July 12;141(28):1392-5. Hypersensitivity reactions to use of mebeverine  pubmed: 9380201